NEWS RELEASE - PRESSEMITTEILUNG

Acino: Preview of 2012 annual results - New CFO appointed

Basle, January 23, 2012, 17.30 hrs - At its meeting today, the Board of Directors ap- praised the provisional annual accounts for 2012 and confirmed the appointment of a new member of Group Management:

2012: Strong top-line growth - exceptional items impact earnings

Acino delivered a strong top-line growth of 91% in 2012 and achieved consolidated annual revenues of EUR 257.1 million (2011: EUR 134.9 million) which meets ambitious expecta- tions and is at the upper end of the guidance of EUR 240-260 million.
Postponed product deliveries due to customer destocking towards year-end, pricing pres- sure in established markets, and higher than expected one-off-expenses relating to the transition of the international business from Mepha to Acino impacted the operational pro- fitability. As a consequence, Acino's EBITDA-margin for the full year 2012 will fail meeting the forecast and is expected to come in at a mid-teens rate. In absolute terms, however, the EBITDA is estimated to be substantially higher than in the prior year.
Supported by a previously announced tax loss carried forward, the Group expects to de- liver a net profit after tax for 2012 which clearly exceeds the 2011 result.
Additional information will become available on March 7, 2013, on the occasion of the pub- lication of the Group's annual results for 2012.

Board of Directors to propose waiving of 2012 dividend

Despite the expected positive net profit, the Board of Directors today decided to propose to the Annual General Meeting of Shareholders of April 4, 2013, the waiving of a dividend distribution. The Board of Directors views this as an exceptional measure to rapidly reduce debt levels (following the acquisition) and to fuel the growth of the company.

2013: Positive outlook confirmed

Based on the volume of orders at hand, Acino reconfirms its positive sales outlook and ex- pects to generate revenues in 2013 beyond the EUR 300 million mark. The integration of the acquired business has been largely completed and important cost savings measures have already been implemented in 2012. These efforts should start to bear fruit in 2013 and will contribute to a marked recovery of the operating margin. A continued weakness of
the Swiss franc against the Euro could further improve profitability since about two thirds of
labor costs incurred are in Swiss francs.

Acino Holding Ltd.

Erlenstrasse 1

CH-4058 Basle

Phone +41 61 338 60 00

Fax +41 61 338 60 80 www.acino-pharma.com

Martin Gertsch appointed as CFO of the Acino Group

Also at today's meeting, Acino's Board named Martin Gertsch as the Group's new Chief Financial Officer and a Member of Group Management effective April 1, 2013. In this func- tion, he will succeed Walter Saladin, who has decided to enter into retirement.
Martin Gertsch is an experienced chief financial officer with extensive expertise in the life science industry and in international markets. Before joining Acino, he served as Vice- President Head of Finance EMEA at the medical device company Synthes Inc. Previously, he held various senior management positions with Delenex Therapeutics and ESBATech, two privately held biotech companies, and the Straumann Group, a global leader in im- plant, restorative and regenerative dentistry. Martin Gertsch is Vice-Chairman of Santhera Pharmaceuticals and a Board Member of Evolva Holding. For additional information please
consult his full profile under www.acino-pharma.com.
"Martin possesses an impressive track record and we consider ourselves very fortunate that he has decided to join our Group. His longstanding experience in finance coupled with his leadership skills will greatly benefit Acino as we continue to advance our businesses," said Peter Burema, CEO of the Acino Group. He added: "I thank Walter for his important contributions during the integration of the international business Acino acquired from Mepha and wish him all the best in his well-deserved retirement."

Acino - Delivering Health

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and interna- tionally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dis- persible forms, transdermal systems and extended release parenterals, for which it also holds pa- tents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house devel- oped products and/or provides customized one-stop solutions from product development and regis- tration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently in 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group is headquartered in Basle, at present has about 850 employees and generated revenues of EUR 129 million in the first half-year 2012.

Contact Calendar

Robert Schmid

Media & Investor Relations Phone +41 61 338 61 15 robert.schmid@acino-pharma.com

www.acino-pharma.com

7.3.2013 Annual Report 2012

7.3.2013 Media and analyst conferences

4.4.2013 General Meeting of Shareholders

Acino Holding Ltd.

Page 2 / 2

Erlenstrasse 1

CH-4058 Basle

Phone +41 61 338 60 00

Fax +41 61 338 60 80 www.acino-pharma.com

distributed by